<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135473</url>
  </required_header>
  <id_info>
    <org_study_id>SEPNET-200304</org_study_id>
    <secondary_id>01 KI 0106 (BMBF)</secondary_id>
    <nct_id>NCT00135473</nct_id>
  </id_info>
  <brief_title>Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)</brief_title>
  <official_title>Prospective Randomized Multicenter Study on the Influence of Colloid vs Crystalloid Volume Resuscitation and of Intensive vs Conventional Insulin Therapy on Outcome in Patients With Severe Sepsis and Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Competence Network Sepsis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>HemoCue Gmbh, Großostheim, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Competence Network Sepsis</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the influence of colloid versus crystalloid volume
      resuscitation and of intensive vs conventional insulin therapy on morbidity and mortality of
      patients with severe sepsis and septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe sepsis and septic shock have a high mortality. Research has concentrated on adjunctive
      sepsis therapies; the role of supportive measures is comparatively unclear. In Europe the use
      of colloids is widespread, but there is no evidence on the role of either crystalloid or
      colloid volume therapy in sepsis. Recently, a higher incidence of kidney failure in sepsis
      was reported after administration of colloids.

      In critical illness, a significant reduction in mortality was recently achieved by strict
      glycemic control, however it has to be determined whether this is true and safe for patients
      with sepsis as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality (28 day)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity (mean sepsis-related organ failure assessment [SOFA] score during intensive care unit length of stay [ICU LOS])</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of acute kidney failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until hemodynamic stabilization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of therapy with vasopressors (in days)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of SOFA sub-scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hemorrhages under hydroxyethyl starch (HES) therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hypoglycemia under intensive insulin therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of critical illness polyneuropathy (CIP)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 day Mortality</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% Hemohes® (10% Hydroxyethyl starch)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterofundin® (Ringer lactate solution)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actrapid® (Insulin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the criteria of &quot;severe sepsis&quot; or &quot;septic shock&quot; according to the
             Society of Critical Care Medicine/American College of Chest Physicians (SCCM/ACCP)
             definitions not longer than 24 hours before ICU admission or 12 hours after ICU
             admission

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Pregnancy

          -  Known allergy against hydroxyethyl starch

          -  Pre-treatment with &gt; 1000ml hydroxyethyl starch within 24 hours before inclusion

          -  Pre-existing kidney failure requiring dialysis or serum creatinine value &gt; 320 mmol/l
             (3,6 mg/dl)

          -  Intracerebral hemorrhage

          -  Severe head trauma with edema

          -  FiO2 at time of study inclusion &gt; 0,7

          -  Heart failure (New York Heart Association [NYHA] IV)

          -  Enrolment in another interventional study

          -  Immune suppression (cytostatic chemotherapy, steroid therapy, AIDS)

          -  Do not resuscitate (DNR) order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad Reinhart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>F.-Schiller-University Jena, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Deufel, MD</last_name>
    <role>Study Director</role>
    <affiliation>F.-Schiller-University Jena, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Löffler, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIVANTES Klinikum Neukölln II</name>
      <address>
        <city>Berlin</city>
        <zip>12313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité I Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Brandenburg GmbH</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Carl-Gustav-Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt-Universität</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg-August-Universität Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle/Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sepsis-gesellschaft.de/DSG/Englisch/SepNet/Research+projects/VISEP?sid=oKhUu07XmwBjbeKacHsxr0&amp;iid=</url>
    <description>Click here for more information about the VISEP study by SepNet</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <keyword>Severe sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>volume substitution</keyword>
  <keyword>intensive insulin therapy</keyword>
  <keyword>colloids</keyword>
  <keyword>crystalloids</keyword>
  <keyword>outcome</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

